Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

As Merck & Co. hunts for an ideal spot to set up a new commercial facility, Delaware is looking to bolster its odds with a cash sweetener. Monday, Delaware’s state investment board approved a $ ...

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...

Explore the universe with news on fascinating discoveries, scientific advancements and more. Trees depicted in famous artworks across a range of styles follow the same mathematical rules as their ...

Tree planting can be the most cost-effective way of removing carbon as long as careful choices are made about which type of trees to plant and where. Governments worldwide have committed to ...

Feb. 20, 2025 — Highly valued economically, ecologically and culturally, the white oak (Quercus alba) is a keystone forest species and is one of the most abundant trees across much of eastern ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Rotting logs turn out to be vital to forest biodiversity and recycling organic matter Katarina Zimmer, Knowable Magazine Though no one may be around to hear when a tree falls in the forest ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...